{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:16:32Z","timestamp":1792512992000,"version":"4.5.0"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00284-025-04597-0","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T08:26:40Z","timestamp":1763454400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cefiderocol: A Comprehensive Review of Chemistry, Mechanisms of Resistance, and Clinical Applications in the Era of Multidrug Resistance"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6465-9449","authenticated-orcid":false,"given":"Mohammad Javad","family":"Roustaye Gourabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7304-1553","authenticated-orcid":false,"given":"Bita","family":"Khanbabaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9651-4833","authenticated-orcid":false,"given":"Yalda","family":"Yarahmadi Saki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9513-8693","authenticated-orcid":false,"given":"Anita","family":"Nikoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1232-8543","authenticated-orcid":false,"given":"Masoud","family":"Kargar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7258-5541","authenticated-orcid":false,"given":"Ali","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5183-6153","authenticated-orcid":false,"given":"Javad","family":"Yasbolaghi Sharahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"1","key":"4597_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciz089","volume":"69","author":"GH Talbot","year":"2019","unstructured":"Talbot GH et al (2019) The infectious diseases society of America\u2019s 10\u00d7\u201920 initiative (10 new systemic antibacterial agents US food and drug administration approved by 2020): is 20\u00d7\u201920 a possibility? Clin Infect Dis 69(1):1\u201311\u00a0https:\/\/doi.org\/10.1093\/cid\/ciz089","journal-title":"Clin Infect Dis"},{"key":"4597_CR2","volume":"201","author":"SMJ Mousavi","year":"2025","unstructured":"Mousavi SMJ et al (2025) Colistin antibacterial activity, clinical effectiveness, and mechanisms of intrinsic and acquired resistance. Microb Pathog 201:107317\u00a0https:\/\/doi.org\/10.1016\/j.micpath.2025.107317","journal-title":"Microb Pathog"},{"issue":"11","key":"4597_CR3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002184","volume":"13","author":"ME de Kraker","year":"2016","unstructured":"de Kraker ME, Stewardson AJ, Harbarth S (2016) Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med 13(11):e1002184\u00a0https:\/\/doi.org\/10.1371\/journal.pmed.1002184","journal-title":"PLoS Med"},{"issue":"4","key":"4597_CR4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1556\/030.2022.01841","volume":"69","author":"JY Sharahi","year":"2022","unstructured":"Sharahi JY et al (2022) Antimicrobial resistance patterns and virulence gene profiles of Salmonella enteritidis and Salmonella typhimurium recovered from patients with gastroenteritis in three cities of Iran. Acta Microbiol Immunol Hung 69(4):323\u2013331 https:\/\/doi.org\/10.1556\/030.2022.01841","journal-title":"Acta Microbiol Immunol Hung"},{"issue":"10459","key":"4597_CR5","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"M Naghavi","year":"2024","unstructured":"Naghavi M et al (2024) Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050. Lancet 404(10459):1199\u20131226 https:\/\/doi.org\/10.1016\/S0140-6736(24)01867-1","journal-title":"Lancet"},{"key":"4597_CR6","unstructured":"Oliveira J, Reygaert W (2023) Gram-Negative Bacteria. StatPearls [Internet]. StatPearls Publishing, Treasure Island. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538213. Accessed 8 Oct 2022"},{"issue":"1","key":"4597_CR7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12941-021-00437-8","volume":"20","author":"JY Sharahi","year":"2021","unstructured":"Sharahi JY et al (2021) Molecular characteristics of antibiotic-resistant Escherichia coli and Klebsiella pneumoniae strains isolated from hospitalized patients in Tehran. Iran Ann Clin Microbiol Antimicrob 20(1):32 https:\/\/doi.org\/10.1186\/s12941-021-00437-8","journal-title":"Iran Ann Clin Microbiol Antimicrob"},{"issue":"3","key":"4597_CR8","doi-asserted-by":"crossref","DOI":"10.4081\/ejtm.2018.7594","volume":"28","author":"SF Hormozi","year":"2018","unstructured":"Hormozi SF et al (2018) Antibiotic resistance in patients suffering from nosocomial infections in Besat hospital. Eur J Transl Myol 28(3):7594 https:\/\/doi.org\/10.4081\/ejtm.2018.7594","journal-title":"Eur J Transl Myol"},{"key":"4597_CR9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40121-020-00286-6","volume":"9","author":"JY Wu","year":"2020","unstructured":"Wu JY, Srinivas P, Pogue JM (2020) Cefiderocol: a novel agent for the management of multidrug-resistant Gram-negative organisms. Infect Dis Ther 9:17\u201340 https:\/\/doi.org\/10.1007\/s40121-020-00286-6","journal-title":"Infect Dis Ther"},{"key":"4597_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2025.03.005","author":"E Keskilidou","year":"2025","unstructured":"Keskilidou E et al (2025) Community and hospital-acquired gram-negative bloodstream infections in non-ICU patients. Am J Infect Control. https:\/\/doi.org\/10.1016\/j.ajic.2025.03.005","journal-title":"Am J Infect Control"},{"issue":"2","key":"4597_CR11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1586\/eri.12.162","volume":"11","author":"N Petrosillo","year":"2013","unstructured":"Petrosillo N et al (2013) Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti-Infect Ther 11(2):159\u2013177 https:\/\/doi.org\/10.1586\/eri.12.162","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"4597_CR12","doi-asserted-by":"crossref","unstructured":"Goudarzi H et al (2023) Evaluation of \u03b2-lactamases and molecular typing of Pseudomonas aeruginosa clinical strains isolated from hospitalized children in Tehran, Iran. Arch Clin Infect Dis 18(2) https:\/\/doi.org\/10.5812\/archcid-134837","DOI":"10.5812\/archcid-134837"},{"issue":"2","key":"4597_CR13","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics12020234","volume":"12","author":"T Karampatakis","year":"2023","unstructured":"Karampatakis T, Tsergouli K, Behzadi P (2023) Carbapenem-resistant Klebsiella pneumoniae: virulence factors, molecular epidemiology and latest updates in treatment options. Antibiotics 12(2):234\u00a0 https:\/\/doi.org\/10.3390\/antibiotics12020234","journal-title":"Antibiotics"},{"key":"4597_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02171-20","author":"EK McCreary","year":"2021","unstructured":"McCreary EK, Heil EL, Tamma PD (2021) New perspectives on antimicrobial agents: cefiderocol. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.02171-20","journal-title":"Antimicrob Agents Chemother"},{"key":"4597_CR15","volume":"8","author":"J Yao","year":"2021","unstructured":"Yao J et al (2021) Cefiderocol: an overview of its in-vitro and in-vivo activity and underlying resistant mechanisms. Front Med 8:741940 https:\/\/doi.org\/10.3389\/fmed.2021.741940","journal-title":"Front Med"},{"issue":"Suppl 2","key":"4597_CR16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.37201\/req\/s02.07.2022","volume":"35","author":"J Mensa","year":"2022","unstructured":"Mensa J, Barber\u00e1n J (2022) Cefiderocol. Summary and conclusions. Rev Esp Quimioter 35(Suppl 2):45 https:\/\/doi.org\/10.37201\/req\/s02.07.2022","journal-title":"Rev Esp Quimioter"},{"issue":"Suppl 7","key":"4597_CR17","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","volume":"69","author":"T Sato","year":"2019","unstructured":"Sato T, Yamawaki K (2019) Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis 69(Suppl 7):S538-s543\u00a0https:\/\/doi.org\/10.1093\/cid\/ciz826","journal-title":"Clin Infect Dis"},{"issue":"Suppl1","key":"4597_CR18","volume":"34","author":"JT Silva","year":"2021","unstructured":"Silva JT, L\u00f3pez-Medrano F (2021) Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria. Rev Esp Quimioter 34(Suppl1):41 https:\/\/doi.org\/10.37201\/req\/s01.12.2021","journal-title":"Rev Esp Quimioter"},{"key":"4597_CR19","doi-asserted-by":"publisher","unstructured":"Ito A et al (2018) In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.01454-17","DOI":"10.1128\/aac.01454-17"},{"issue":"7","key":"4597_CR20","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1089\/mdr.2019.0298","volume":"26","author":"A Iregui","year":"2020","unstructured":"Iregui A et al (2020) Activity of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii endemic to medical centers in New York City. Microb Drug Resist 26(7):722\u2013726 https:\/\/doi.org\/10.1089\/mdr.2019.0298","journal-title":"Microb Drug Resist"},{"issue":"1","key":"4597_CR21","doi-asserted-by":"crossref","DOI":"10.1186\/s13613-023-01146-5","volume":"13","author":"P Viale","year":"2023","unstructured":"Viale P et al (2023) Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence. Ann Intensive Care 13(1):52 https:\/\/doi.org\/10.1186\/s13613-023-01146-5","journal-title":"Ann Intensive Care"},{"issue":"4","key":"4597_CR22","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics12040785","volume":"12","author":"M Padovani","year":"2023","unstructured":"Padovani M et al (2023) In vitro activity of cefiderocol on multiresistant bacterial strains and genomic analysis of two cefiderocol resistant strains. Antibiotics 12(4):785 https:\/\/doi.org\/10.3390\/antibiotics12040785","journal-title":"Antibiotics"},{"issue":"12","key":"4597_CR23","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/1060028020929988","volume":"54","author":"RM El-Lababidi","year":"2020","unstructured":"El-Lababidi RM, Rizk JG (2020) Cefiderocol: a siderophore cephalosporin. Ann Pharmacother 54(12):1215\u20131231\u00a0 https:\/\/doi.org\/10.1177\/1060028020929988","journal-title":"Ann Pharmacother"},{"key":"4597_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12112532","author":"B Yousefi","year":"2024","unstructured":"Yousefi B et al (2024) Cefiderocol in combating carbapenem-resistant Acinetobacter baumannii: action and resistance. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12112532","journal-title":"Biomedicines"},{"issue":"Supplement_7","key":"4597_CR25","doi-asserted-by":"crossref","first-page":"S544","DOI":"10.1093\/cid\/ciz827","volume":"69","author":"Y Yamano","year":"2019","unstructured":"Yamano Y (2019) In vitro activity of Cefiderocol against a broad range of clinically important gram-negative bacteria. Clin Infect Dis 69(Supplement_7):S544\u2013S551 https:\/\/doi.org\/10.1093\/cid\/ciz827","journal-title":"Clin Infect Dis"},{"issue":"2","key":"4597_CR26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink RG et al (2021) Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 21(2):213\u2013225 https:\/\/doi.org\/10.1016\/S1473-3099(20)30731-3","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"4597_CR27","doi-asserted-by":"crossref","first-page":"e1103","DOI":"10.1093\/cid\/ciaa1799","volume":"72","author":"S Naseer","year":"2020","unstructured":"Naseer S et al (2020) US Food and Drug Administration (FDA): benefit-risk considerations for cefiderocol (Fetroja\u00ae). Clin Infect Dis 72(12):e1103\u2013e1111 https:\/\/doi.org\/10.1093\/cid\/ciaa1799","journal-title":"Clin Infect Dis"},{"key":"4597_CR28","doi-asserted-by":"crossref","unstructured":"Vila AJ et al (2025) P-1370. molecular bases and mechanistic insights of NDM-mediated resistance to Cefiderocol. Open Forum Infect Dis https:\/\/doi.org\/10.1093\/ofid\/ofae631.1547","DOI":"10.1093\/ofid\/ofae631.1547"},{"key":"4597_CR29","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s40262-021-01063-5","volume":"60","author":"M Bilal","year":"2021","unstructured":"Bilal M et al (2021) Clinical pharmacokinetics and pharmacodynamics of cefiderocol. Clin Pharmacokinet 60:1495\u20131508\u00a0 https:\/\/doi.org\/10.1007\/s40262-021-01063-5","journal-title":"Clin Pharmacokinet"},{"key":"4597_CR30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","volume":"79","author":"GG Zhanel","year":"2019","unstructured":"Zhanel GG et al (2019) Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs 79:271\u2013289 https:\/\/doi.org\/10.1007\/s40265-019-1055-2","journal-title":"Drugs"},{"issue":"Supplement_7","key":"4597_CR31","doi-asserted-by":"crossref","first-page":"S552","DOI":"10.1093\/cid\/ciz828","volume":"69","author":"T Katsube","year":"2019","unstructured":"Katsube T, Echols R, Wajima T (2019) Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin. Clin Infect Dis 69(Supplement_7):S552\u2013S558 https:\/\/doi.org\/10.1093\/cid\/ciz828","journal-title":"Clin Infect Dis"},{"issue":"7","key":"4597_CR32","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/jcph.1386","volume":"59","author":"S Miyazaki","year":"2019","unstructured":"Miyazaki S et al (2019) Metabolism, excretion, and pharmacokinetics of [14C]-cefiderocol (S-649266), a siderophore cephalosporin, in healthy subjects following intravenous administration. J Clin Pharmacol 59(7):958\u2013967\u00a0 https:\/\/doi.org\/10.1002\/jcph.1386.","journal-title":"J Clin Pharmacol"},{"key":"4597_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02163-17","author":"Y Saisho","year":"2018","unstructured":"Saisho Y et al (2018) Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.02163-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4597_CR34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112791","volume":"208","author":"D Al Shaer","year":"2020","unstructured":"Al Shaer D et al (2020) Hydroxamate siderophores: natural occurrence, chemical synthesis, iron binding affinity and use as Trojan horses against pathogens. Eur J Med Chem 208:112791\u00a0 https:\/\/doi.org\/10.1016\/j.ejmech.2020.112791","journal-title":"Eur J Med Chem"},{"key":"4597_CR35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112667","volume":"205","author":"S Yuan","year":"2020","unstructured":"Yuan S, Yu B, Liu H-M (2020) New drug approvals for 2019: synthesis and clinical applications. Eur J Med Chem 205:112667 https:\/\/doi.org\/10.1016\/j.ejmech.2020.112667","journal-title":"Eur J Med Chem"},{"issue":"13","key":"4597_CR36","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40265-021-01580-4","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY (2021) Cefiderocol: a review in serious Gram-negative bacterial infections. Drugs 81(13):1559\u20131571 https:\/\/doi.org\/10.1007\/s40265-021-01580-4","journal-title":"Drugs"},{"issue":"Supplement_7","key":"4597_CR37","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","volume":"69","author":"T Sato","year":"2019","unstructured":"Sato T, Yamawaki K (2019) Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis 69(Supplement_7):S538\u2013S543 https:\/\/doi.org\/10.1093\/cid\/ciz826","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4597_CR38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106376","volume":"90","author":"S Soueges","year":"2025","unstructured":"Soueges S et al (2025) Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-ID. J Infect 90(1):106376 https:\/\/doi.org\/10.1016\/j.jinf.2024.106376","journal-title":"J Infect"},{"issue":"Suppl 1","key":"4597_CR39","doi-asserted-by":"crossref","DOI":"10.37201\/req\/s01.08.2021","volume":"35","author":"MC Soriano","year":"2022","unstructured":"Soriano MC, Montufar J, Blandino-Ortiz A (2022) Cefiderocol. Rev Esp Quimioter 35(Suppl 1):31 https:\/\/doi.org\/10.37201\/req\/s01.07.2022","journal-title":"Rev Esp Quimioter"},{"key":"4597_CR40","doi-asserted-by":"crossref","unstructured":"Takemura M et al (2020) 1252. In vitro activity of cefiderocol against metallo-\u03b2-lactamase-producing gram-negative bacteria collected in North America and Europe Between 2014 and 2017: SIDERO-WT-2014\u20132016 Studies. in Open Forum Infectious Diseases. Oxford University Press, Oxford https:\/\/doi.org\/10.1093\/ofid\/ofaa439.1436","DOI":"10.1093\/ofid\/ofaa439.1436"},{"issue":"12","key":"4597_CR41","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1093\/jac\/dkae359","volume":"79","author":"M Sanz-Codina","year":"2024","unstructured":"Sanz-Codina M et al (2024) Target-site cefiderocol pharmacokinetics in soft tissues of healthy volunteers. J Antimicrob Chemother 79(12):3281\u20133288\u00a0https:\/\/doi.org\/10.1093\/jac\/dkae359","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"4597_CR42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.37201\/req\/s02.04.2022","volume":"35","author":"JRA Perea","year":"2022","unstructured":"Perea JRA, de Rada BSD (2022) Pharmacokinetics\/pharmacodynamics and tolerability of cefiderocol in the clinical setting. Rev Esp Quimioter 35(Suppl 2):28 https:\/\/doi.org\/10.37201\/req\/s02.04.2022","journal-title":"Rev Esp Quimioter"},{"key":"4597_CR43","doi-asserted-by":"crossref","unstructured":"Campogiani L et al (2023) Real-life data on cefiderocol efficacy and safety to treat multidrug-resistant Acinetobacter baumannii infections. in Open Forum Infectious Diseases. Oxford University Press, Oxford https:\/\/doi.org\/10.1093\/ofid\/ofad627","DOI":"10.1093\/ofid\/ofad627"},{"issue":"11","key":"4597_CR44","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1093\/jac\/dky317","volume":"73","author":"A Ito","year":"2018","unstructured":"Ito A et al (2018) Stability and low induction propensity of cefiderocol against chromosomal AmpC \u03b2-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae. J Antimicrob Chemother 73(11):3049\u20133052\u00a0 https:\/\/doi.org\/10.1093\/jac\/dky317","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"4597_CR45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106723","volume":"61","author":"A Karruli","year":"2023","unstructured":"Karruli A et al (2023) Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience. Int J Antimicrob Agents 61(2):106723 https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106723","journal-title":"Int J Antimicrob Agents"},{"key":"4597_CR46","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S475462","author":"CJ Clancy","year":"2024","unstructured":"Clancy CJ et al (2024) Effectiveness and safety of cefiderocol in clinical practice for treatment of patients with Gram-negative bacterial infections: US interim results of the PROVE study. Infect Drug Resist. https:\/\/doi.org\/10.2147\/IDR.S475462","journal-title":"Infect Drug Resist"},{"key":"4597_CR47","unstructured":"https:\/\/www.drugs.com\/history\/fetroja.html"},{"key":"4597_CR48","doi-asserted-by":"crossref","unstructured":"Matsunaga Y et al (2020) 1292. Safety profile of the novel siderophore cephalosporin Cefiderocol in randomized phase 2 and phase 3 clinical studies of serious gram-negative infections. in Open Forum Infectious Diseases. Oxford University Press, 2020 https:\/\/doi.org\/10.1093\/ofid\/ofaa439.1475","DOI":"10.1093\/ofid\/ofaa439.1475"},{"issue":"Suppl 2(Suppl 2","key":"4597_CR49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.37201\/req\/s02.02.2022","volume":"35","author":"A Soriano","year":"2022","unstructured":"Soriano A, Mensa J (2022) Mechanism of action of cefiderocol. Rev Esp Quimioter 35(Suppl 2(Suppl 2)):16\u201319 https:\/\/doi.org\/10.37201\/req\/s02.02.2022","journal-title":"Rev Esp Quimioter"},{"issue":"1","key":"4597_CR50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40121-020-00286-6","volume":"9","author":"JY Wu","year":"2020","unstructured":"Wu JY, Srinivas P, Pogue JM (2020) Cefiderocol: a novel agent for the management of multidrug-resistant gram-negative organisms. Infect Dis Ther 9(1):17\u201340 https:\/\/doi.org\/10.1007\/s40121-020-00286-6","journal-title":"Infect Dis Ther"},{"key":"4597_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11060723","author":"S Karakonstantis","year":"2022","unstructured":"Karakonstantis S, Rousaki M, Kritsotakis EI (2022) Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics11060723","journal-title":"Antibiotics"},{"issue":"3","key":"4597_CR52","volume":"11","author":"SH Moon","year":"2023","unstructured":"Moon SH, Huang E (2023) Cefiderocol resistance in Klebsiella pneumoniae is linked to SHV extended-spectrum \u03b2-lactamase activities and functional loss of the outer membrane porin OmpK35. Microbiol Spectr 11(3):e0349622\u00a0 https:\/\/doi.org\/10.1128\/spectrum.03496-22","journal-title":"Microbiol Spectr"},{"key":"4597_CR53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jgar.2023.06.003","volume":"34","author":"L Brakert","year":"2023","unstructured":"Brakert L et al (2023) Rapid development of cefiderocol resistance in a carbapenem-resistant Pseudomonas aeruginosa isolate associated with mutations in the pyoverdine biosynthesis pathway. J Glob Antimicrob Resist 34:59\u201362 https:\/\/doi.org\/10.1016\/j.jgar.2023.06.003","journal-title":"J Glob Antimicrob Resist"},{"issue":"5","key":"4597_CR54","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciab511","volume":"74","author":"S Klein","year":"2021","unstructured":"Klein S et al (2021) Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cirA. Clin Infect Dis 74(5):905\u2013908 https:\/\/doi.org\/10.1093\/cid\/ciab511","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4597_CR55","volume":"10","author":"Q Wang","year":"2022","unstructured":"Wang Q et al (2022) Occurrence of high levels of cefiderocol resistance in carbapenem-resistant Escherichia coli before its approval in China: a report from China CRE-network. Microbiol Spectr 10(3):e02670-e2721 https:\/\/doi.org\/10.1128\/spectrum.02670-21","journal-title":"Microbiol Spectr"},{"key":"4597_CR56","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01454-17","author":"A Ito","year":"2018","unstructured":"Ito A et al (2018) In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01454-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"4597_CR57","doi-asserted-by":"crossref","first-page":"e01507","DOI":"10.1128\/aac.01507-23","volume":"68","author":"JA Freiberg","year":"2024","unstructured":"Freiberg JA et al (2024) A multi-species outbreak of VIM-producing carbapenem-resistant bacteria in a burn unit and subsequent investigation of rapid development of cefiderocol resistance. Antimicrob Agents Chemother 68(4):e01507-e1523 https:\/\/doi.org\/10.1128\/aac.01507-23","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"4597_CR58","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.01779-21","volume":"9","author":"CL McElheny","year":"2021","unstructured":"McElheny CL et al (2021) In vitro evolution of cefiderocol resistance in an NDM-producing Klebsiella pneumoniae due to functional loss of CirA. Microbiol Spectr 9(3):e0177921 https:\/\/doi.org\/10.1128\/Spectrum.01779-21","journal-title":"Microbiol Spectr"},{"key":"4597_CR59","unstructured":"Yamano Y et al (2020) Frequency of resistance acquisition and resistance mechanisms to cefiderocol. in ID Week Annual Meeting"},{"key":"4597_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1480322","author":"L Morosi","year":"2024","unstructured":"Morosi L et al (2024) Distinct chromosomal mutation associated with cefiderocol resistance in Acinetobacter baumannii: a combined bioinformatics and mass spectrometry approach to unveil and validate the in vivo-acquired chemoresistance. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2024.1480322","journal-title":"Front Microbiol"},{"issue":"11","key":"4597_CR61","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41429-024-00762-y","volume":"77","author":"R Kriz","year":"2024","unstructured":"Kriz R et al (2024) In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol. J Antibiot 77(11):757\u2013767\u00a0 https:\/\/doi.org\/10.1038\/s41429-024-00762-y","journal-title":"J Antibiot"},{"key":"4597_CR62","doi-asserted-by":"crossref","unstructured":"Liu X et al (2023) Mutation in the two-component regulator BaeSR mediates cefiderocol resistance and enhances virulence in Acinetobacter baumannii. mSystems 8(4):e0129122 https:\/\/doi.org\/10.1128\/msystems.01291-22","DOI":"10.1128\/msystems.01291-22"},{"issue":"12","key":"4597_CR63","doi-asserted-by":"crossref","first-page":"14132","DOI":"10.3390\/cimb46120846","volume":"46","author":"G Bianco","year":"2024","unstructured":"Bianco G et al (2024) Updates on the activity, efficacy and emerging mechanisms of resistance to cefiderocol. Curr Issues Mol Biol 46(12):14132\u201314153 https:\/\/doi.org\/10.3390\/cimb46120846","journal-title":"Curr Issues Mol Biol"},{"issue":"3","key":"4597_CR64","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01928-24","volume":"13","author":"J Vi\u00f1es","year":"2025","unstructured":"Vi\u00f1es J et al (2025) Novel PiuC, PirA, and PiuA mutations leading to in vivo cefiderocol resistance progression in IMP-16- and KPC-2-producing Pseudomonas aeruginosa from a leukemic patient. Microbiol Spectr 13(3):e01928\u201324 https:\/\/doi.org\/10.1128\/spectrum.01928-24","journal-title":"Microbiol Spectr"},{"issue":"8","key":"4597_CR65","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41579-023-00877-3","volume":"21","author":"WPJ Smith","year":"2023","unstructured":"Smith WPJ et al (2023) Bacterial defences: mechanisms, evolution and antimicrobial resistance. Nat Rev Microbiol 21(8):519\u2013534 https:\/\/doi.org\/10.1038\/s41579-023-00877-3","journal-title":"Nat Rev Microbiol"},{"issue":"Suppl 2(Suppl 2","key":"4597_CR66","doi-asserted-by":"crossref","first-page":"45","DOI":"10.37201\/req\/s02.07.2022","volume":"35","author":"J Mensa","year":"2022","unstructured":"Mensa J, Barber\u00e1n J (2022) Cefiderocol. Summary and conclusions. Rev Esp Quimioter 35(Suppl 2(Suppl 2)):45\u201347 https:\/\/doi.org\/10.37201\/req\/s02.07.2022","journal-title":"Rev Esp Quimioter"},{"issue":"9","key":"4597_CR67","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1093\/jac\/dkac221","volume":"77","author":"C Fr\u00f6hlich","year":"2022","unstructured":"Fr\u00f6hlich C et al (2022) Evolution of \u03b2-lactamase-mediated cefiderocol resistance. J Antimicrob Chemother 77(9):2429\u20132436 https:\/\/doi.org\/10.1093\/jac\/dkac221","journal-title":"J Antimicrob Chemother"},{"key":"4597_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae183","author":"K Kocer","year":"2024","unstructured":"Kocer K et al (2024) Investigation of cefiderocol resistance prevalence and resistance mechanisms in carbapenem-resistant Pseudomonas aeruginosa, Germany 2019\u201321. JAC-Antimicrobial Resistance. https:\/\/doi.org\/10.1093\/jacamr\/dlae183","journal-title":"JAC-Antimicrobial Resistance"},{"issue":"3","key":"4597_CR69","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01928-24","volume":"13","author":"J Vi\u00f1es","year":"2025","unstructured":"Vi\u00f1es J et al (2025) Novel PiuC, PirA, and PiuA mutations leading to in vivo cefiderocol resistance progression in IMP-16- and KPC-2-producing Pseudomonas aeruginosa from a leukemic patient. Microbiol Spectr 13(3):e01928-e2024 https:\/\/doi.org\/10.1128\/spectrum.01928-24","journal-title":"Microbiol Spectr"},{"issue":"4","key":"4597_CR70","volume":"60","author":"P Lan","year":"2022","unstructured":"Lan P et al (2022) Catecholate siderophore receptor CirA impacts cefiderocol susceptibility in Klebsiella pneumoniae. Int J Antimicrob Agents 60(4):106646 https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106646","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"4597_CR71","volume":"12","author":"KevinR Barker","year":"2024","unstructured":"Barker Kevin R et al (2024) When the Trojan horse is unable to reach inside the city: investigation of the mechanism of resistance behind the first reported cefiderocol-resistant E. coli in Canada. Microbiol Spectr 12(5):e03223\u201323 https:\/\/doi.org\/10.1128\/spectrum.03223-23","journal-title":"Microbiol Spectr"},{"issue":"2","key":"4597_CR72","volume":"16","author":"L Zhang","year":"2024","unstructured":"Zhang L et al (2024) Bacterial efflux pump inhibitors reduce antibiotic resistance. Pharmaceutics 16(2):170 https:\/\/doi.org\/10.3390\/pharmaceutics16020170","journal-title":"Pharmaceutics"},{"key":"4597_CR73","doi-asserted-by":"crossref","unstructured":"Ikawa S et al (2022) Role of the drug efflux pump in the intrinsic cefiderocol resistance of Pseudomonas aeruginosa. bioRxiv 2022.05.31.494263 https:\/\/doi.org\/10.1101\/2022.05.31.494263","DOI":"10.1101\/2022.05.31.494263"},{"key":"4597_CR74","doi-asserted-by":"crossref","unstructured":"Liu X et al (2023) Mutation in the two-component regulator BaeSR mediates cefiderocol resistance and enhances virulence in Acinetobacter baumannii. mSystems 8(4):e01291\u201322 https:\/\/doi.org\/10.1128\/msystems.01291-22","DOI":"10.1128\/msystems.01291-22"},{"key":"4597_CR75","doi-asserted-by":"crossref","DOI":"10.1016\/j.anaerobe.2020.102179","volume":"62","author":"M Park","year":"2020","unstructured":"Park M, Sutherland JB, Rafii F (2020) \u03b2-lactam resistance development affects binding of penicillin-binding proteins (PBPs) of Clostridium perfringens to the fluorescent penicillin, BOCILLIN FL. Anaerobe 62:102179\u00a0 https:\/\/doi.org\/10.1016\/j.anaerobe.2020.102179","journal-title":"Anaerobe"},{"issue":"10","key":"4597_CR76","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1093\/jac\/dkac241","volume":"77","author":"C Lasarte-Monterrubio","year":"2022","unstructured":"Lasarte-Monterrubio C et al (2022) Activity of cefiderocol, imipenem\/relebactam, cefepime\/taniborbactam and cefepime\/zidebactam against ceftolozane\/tazobactam- and ceftazidime\/avibactam-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 77(10):2809\u20132815 https:\/\/doi.org\/10.1093\/jac\/dkac241","journal-title":"J Antimicrob Chemother"},{"key":"4597_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00054","author":"M Mishra","year":"2020","unstructured":"Mishra M et al (2020) Antibiotic resistance profile, outer membrane proteins, virulence factors and genome sequence analysis reveal clinical isolates of enterobacter are potential pathogens compared to environmental isolates. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2020.00054","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"4597_CR78","volume":"11","author":"H Moon Sun","year":"2023","unstructured":"Moon Sun H, Huang E (2023) Cefiderocol resistance in Klebsiella pneumoniae is linked to SHV extended-spectrum \u03b2-lactamase activities and functional loss of the outer membrane porin OmpK35. Microbiol Spectr 11(3):e03496\u201322\u00a0 https:\/\/doi.org\/10.1128\/spectrum.03496-22","journal-title":"Microbiol Spectr"},{"key":"4597_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.987011","author":"NK Devanga Ragupathi","year":"2022","unstructured":"Devanga Ragupathi NK et al (2022) Editorial: Biofilm-mediated nosocomial infections and its association with antimicrobial resistance: detection, prevention, and management. Front Med. https:\/\/doi.org\/10.3389\/fmed.2022.987011","journal-title":"Front Med"},{"key":"4597_CR80","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jgar.2025.04.010","volume":"43","author":"G Fabrizio","year":"2025","unstructured":"Fabrizio G et al (2025) Cefiderocol activity against planktonic and biofilm forms of \u03b2-lactamase-producing Pseudomonas aeruginosa from people with cystic fibrosis. J Glob Antimicrob Resist 43:111\u2013119\u00a0 https:\/\/doi.org\/10.1016\/j.jgar.2025.04.010","journal-title":"J Glob Antimicrob Resist"},{"issue":"Suppl 2","key":"4597_CR81","doi-asserted-by":"crossref","first-page":"28","DOI":"10.37201\/req\/s02.04.2022","volume":"35","author":"JR Azanza Perea","year":"2022","unstructured":"Azanza Perea JR, D\u00edaz S\u00e1daba, de Rada B (2022) Pharmacokinetics\/Pharmacodynamics and tolerability of cefiderocol in the clinical setting. Rev Esp Quimioter 35(Suppl 2):28\u201334 https:\/\/doi.org\/10.37201\/req\/s02.04.2022","journal-title":"Rev Esp Quimioter"},{"issue":"5","key":"4597_CR82","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1007\/s12325-025-03147-1","volume":"42","author":"C Zhang","year":"2025","unstructured":"Zhang C et al (2025) Pharmacokinetic, pharmacokinetic\/pharmacodynamic, and safety investigations of cefiderocol in Chinese healthy subjects. Adv Ther 42(5):2285\u20132297 https:\/\/doi.org\/10.1007\/s12325-025-03147-1","journal-title":"Adv Ther"},{"issue":"2","key":"4597_CR83","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/INF.0000000000004529","volume":"44","author":"JS Bradley","year":"2025","unstructured":"Bradley JS et al (2025) Pharmacokinetics, safety and tolerability of single-dose or multiple-dose cefiderocol in hospitalized pediatric patients three months to less than eighteen years old with infections treated with standard-of-care antibiotics in the PEDI-CEFI phase 2 study. Pediatr Infect Dis J 44(2):136\u2013142 https:\/\/doi.org\/10.1097\/INF.0000000000004529","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"4597_CR84","volume":"12","author":"P-H Wicky","year":"2023","unstructured":"Wicky P-H et al (2023) Cefiderocol treatment for severe infections due to difficult-to-treat-resistant non-fermentative gram-negative Bacilli in ICU patients: a case series and narrative literature review. Antibiotics 12(6):991 https:\/\/doi.org\/10.3390\/antibiotics12060991","journal-title":"Antibiotics"},{"key":"4597_CR85","doi-asserted-by":"crossref","DOI":"10.1177\/17562872211065570","volume":"14","author":"H Wang","year":"2022","unstructured":"Wang H, Palasik BN (2022) Combating antimicrobial resistance with cefiderocol for complicated infections involving the urinary tract. Ther Adv Urol 14:17562872211065570 https:\/\/doi.org\/10.1177\/17562872211065570","journal-title":"Ther Adv Urol"},{"key":"4597_CR86","doi-asserted-by":"publisher","unstructured":"Kawaguchi N et al (2021) Population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection\/sepsis, or complicated urinary tract infection. Antimicrob Agents Chemother 65(3):https:\/\/doi.org\/10.1128\/aac.01437-20","DOI":"10.1128\/aac.01437-20"},{"issue":"1","key":"4597_CR87","first-page":"e01539","volume":"69","author":"C Koenig","year":"2024","unstructured":"Koenig C et al (2024) Cefiderocol pharmacokinetics during acute pulmonary exacerbations in hospitalized adult persons with cystic fibrosis. Antimicrob Agents Chemother 69(1):e01539-e1624\u00a0 https:\/\/doi.org\/10.1128\/aac.01539-24","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"4597_CR88","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jpha.2015.11.005","volume":"6","author":"M Balouiri","year":"2016","unstructured":"Balouiri M, Sadiki M, Ibnsouda SK (2016) Methods for in vitro evaluating antimicrobial activity: a review. J Pharm Anal 6(2):71\u201379 https:\/\/doi.org\/10.1016\/j.jpha.2015.11.005","journal-title":"J Pharm Anal"},{"issue":"Suppl 2","key":"4597_CR89","doi-asserted-by":"crossref","first-page":"20","DOI":"10.37201\/req\/s02.03.2022","volume":"35","author":"D Gij\u00f3n Cordero","year":"2022","unstructured":"Gij\u00f3n Cordero D et al (2022) Antibacterial spectrum of cefiderocol. Rev Esp Quimioter 35(Suppl 2):20\u201327 https:\/\/doi.org\/10.37201\/req\/s02.03.2022","journal-title":"Rev Esp Quimioter"},{"issue":"6","key":"4597_CR90","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/jac\/dkac080","volume":"77","author":"E Matuschek","year":"2022","unstructured":"Matuschek E et al (2022) Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing. J Antimicrob Chemother 77(6):1662\u20131669 https:\/\/doi.org\/10.1093\/jac\/dkac080","journal-title":"J Antimicrob Chemother"},{"key":"4597_CR91","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01649-20","author":"CP Morris","year":"2020","unstructured":"Morris CP et al (2020) Cefiderocol antimicrobial susceptibility testing against multidrug-resistant gram-negative bacilli: a comparison of disk diffusion to broth microdilution. J Clin Microbiol. https:\/\/doi.org\/10.1128\/jcm.01649-20","journal-title":"J Clin Microbiol"},{"key":"4597_CR92","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00951-20","author":"PJ Simner","year":"2020","unstructured":"Simner PJ, Patel R (2020) Cefiderocol antimicrobial susceptibility testing considerations: the achilles\u2019 heel of the trojan horse? J Clin Microbiol. https:\/\/doi.org\/10.1128\/jcm.00951-20","journal-title":"J Clin Microbiol"},{"issue":"2","key":"4597_CR93","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10020165","volume":"10","author":"B Kowalska-Krochmal","year":"2021","unstructured":"Kowalska-Krochmal B, Dudek-Wicher R (2021) The minimum inhibitory concentration of antibiotics: methods, interpretation, clinical relevance. Pathogens 10(2):165\u00a0 https:\/\/doi.org\/10.3390\/pathogens10020165","journal-title":"Pathogens"},{"issue":"6","key":"4597_CR94","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/jac\/dkab015","volume":"76","author":"KA Parsels","year":"2021","unstructured":"Parsels KA et al (2021) Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections. J Antimicrob Chemother 76(6):1379\u20131391 https:\/\/doi.org\/10.1093\/jac\/dkab015","journal-title":"J Antimicrob Chemother"},{"key":"4597_CR95","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01767-19","author":"JM Kidd","year":"2019","unstructured":"Kidd JM, Abdelraouf K, Nicolau DP (2019) Efficacy of humanized cefiderocol exposure is unaltered by host iron overload in the thigh infection model. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.01767-19","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"4597_CR96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277946","volume":"17","author":"L Daoud","year":"2022","unstructured":"Daoud L et al (2022) Elucidating the effect of iron acquisition systems in Klebsiella pneumoniae on susceptibility to the novel siderophore-cephalosporin cefiderocol. PLoS One 17(12):e0277946 https:\/\/doi.org\/10.1371\/journal.pone.0277946","journal-title":"PLoS One"},{"key":"4597_CR97","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad107","author":"RK Shields","year":"2023","unstructured":"Shields RK et al (2023) In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel \u03b2-lactam\/\u03b2-lactamase inhibitors. JAC-Antimicrobial Resistance. https:\/\/doi.org\/10.1093\/jacamr\/dlad107","journal-title":"JAC-Antimicrobial Resistance"},{"issue":"2","key":"4597_CR98","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/jac\/dkad396","volume":"79","author":"CM Gill","year":"2023","unstructured":"Gill CM et al (2023) In vitro activity of cefiderocol against a global collection of carbapenem-resistant Pseudomonas aeruginosa with a high level of carbapenemase diversity. J Antimicrob Chemother 79(2):412\u2013416 https:\/\/doi.org\/10.1093\/jac\/dkad396","journal-title":"J Antimicrob Chemother"},{"key":"4597_CR99","doi-asserted-by":"crossref","unstructured":"Takemura M et al (2023) In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates. Antimicrob Agents Chemother 67(12):e00346-23 https:\/\/doi.org\/10.1128\/aac.00346-23","DOI":"10.1128\/aac.00346-23"},{"key":"4597_CR100","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01454-17","author":"A Ito","year":"2018","unstructured":"Ito A et al (2018) In vitro antibacterial properties of Cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.01454-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"4597_CR101","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/1348-0421.12887","volume":"65","author":"Y Akeda","year":"2021","unstructured":"Akeda Y (2021) Current situation of carbapenem-resistant Enterobacteriaceae and Acinetobacter in Japan and Southeast Asia. Microbiol Immunol 65(6):229\u2013237 https:\/\/doi.org\/10.1111\/1348-0421.12887","journal-title":"Microbiol Immunol"},{"issue":"2","key":"4597_CR102","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M et al (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21(2):226\u2013240\u00a0 https:\/\/doi.org\/10.1016\/S1473-3099(20)30796-9","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"4597_CR103","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/14787210.2022.2071701","volume":"20","author":"R Canton","year":"2022","unstructured":"Canton R, Yohei D, Simner PJ (2022) Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: a case for cefiderocol. Expert Rev Anti-infect Ther 20(8):1077\u20131094 https:\/\/doi.org\/10.1080\/14787210.2022.2071701","journal-title":"Expert Rev Anti-infect Ther"},{"issue":"5","key":"4597_CR104","volume":"10","author":"Y Wang","year":"2022","unstructured":"Wang Y et al (2022) Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria. Ann Transl Med 10(5):261 https:\/\/doi.org\/10.21037\/atm-22-889","journal-title":"Ann Transl Med"},{"issue":"12","key":"4597_CR105","doi-asserted-by":"crossref","first-page":"e00735","DOI":"10.1128\/aac.00735-23","volume":"67","author":"J Zhao","year":"2023","unstructured":"Zhao J et al (2023) In vitro activity of cefiderocol, a siderophore cephalosporin, against carbapenem-resistant hypervirulent Klebsiella pneumoniae in China. Antimicrob Agents Chemother 67(12):e00735-e823 https:\/\/doi.org\/10.1128\/aac.00735-23","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"4597_CR106","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/jac\/dkad298","volume":"78","author":"M Piccica","year":"2023","unstructured":"Piccica M et al (2023) Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience. J Antimicrob Chemother 78(11):2752\u20132761 https:\/\/doi.org\/10.1093\/jac\/dkad298","journal-title":"J Antimicrob Chemother"},{"key":"4597_CR107","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmmb.2024.100556","volume":"48","author":"H Khanchandani","year":"2024","unstructured":"Khanchandani H et al (2024) In vitro activity of the newly approved antimicrobial agent cefiderocol against carbapenem resistant Gram negative clinical isolates. Indian J Med Microbiol 48:100556\u00a0 https:\/\/doi.org\/10.1016\/j.ijmmb.2024.100556","journal-title":"Indian J Med Microbiol"},{"issue":"12","key":"4597_CR108","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s10096-022-04503-7","volume":"41","author":"W Ni","year":"2022","unstructured":"Ni W et al (2022) In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 41(12):1451\u20131457\u00a0 https:\/\/doi.org\/10.1007\/s10096-022-04503-7","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"4597_CR109","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jiph.2023.06.009","volume":"16","author":"F Cal\u00f2","year":"2023","unstructured":"Cal\u00f2 F et al (2023) Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: a multicenter observational study. J Infect Public Health 16(9):1485\u20131491\u00a0 https:\/\/doi.org\/10.1016\/j.jiph.2023.06.009","journal-title":"J Infect Public Health"},{"issue":"2","key":"4597_CR110","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s15010-022-01933-5","volume":"51","author":"V Gavaghan","year":"2023","unstructured":"Gavaghan V, Miller JL, Dela-Pena J (2023) Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections. Infection 51(2):475\u2013482 https:\/\/doi.org\/10.1007\/s15010-022-01933-5","journal-title":"Infection"},{"key":"4597_CR111","doi-asserted-by":"crossref","unstructured":"Kaiserman J et al (2023) The Oxindole GW-5074 inhibits JC polyomavirus infection and spread by antagonizing the MAPK-ERK signaling pathway. mBio 14(2):e03583-22 https:\/\/doi.org\/10.1128\/mbio.03583-22","DOI":"10.1128\/mbio.03583-22"},{"key":"4597_CR112","doi-asserted-by":"crossref","unstructured":"Zhi Q et al (2024) What role do biocontrol agents with Mg2+ play in the fate of antibiotic resistome and pathogenic bacteria in the phyllosphere? mSystems 9(4):e01126-23 https:\/\/doi.org\/10.1128\/msystems.01126-23","DOI":"10.1128\/msystems.01126-23"},{"issue":"Supplement_3","key":"4597_CR113","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkab246","volume":"76","author":"D Bouzid","year":"2021","unstructured":"Bouzid D et al (2021) Systematic review on the association between respiratory virus real-time PCR cycle threshold values and clinical presentation or outcomes. J Antimicrob Chemother 76(Supplement_3):iii33\u2013iii49\u00a0 https:\/\/doi.org\/10.1093\/jac\/dkab246","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"4597_CR114","volume":"3","author":"T San","year":"2021","unstructured":"San T et al (2021) High burden of infections caused by ESBL-producing MDR Escherichia coli in paediatric patients, Yangon, Myanmar. JAC-Antimicrobial Resistance 3(1):dlab011 https:\/\/doi.org\/10.1093\/jacamr\/dlab011","journal-title":"JAC-Antimicrobial Resistance"},{"issue":"12","key":"4597_CR115","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1093\/jac\/dkab306","volume":"76","author":"M Castanheira","year":"2021","unstructured":"Castanheira M et al (2021) Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime\/avibactam, meropenem\/vaborbactam and comparators against these isolates. J Antimicrob Chemother 76(12):3125\u20133134\u00a0 https:\/\/doi.org\/10.1093\/jac\/dkab306","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"4597_CR116","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/cid\/ciad290","volume":"77","author":"K Romanowski","year":"2023","unstructured":"Romanowski K et al (2023) Healthcare utilization after respiratory tuberculosis: a controlled interrupted time series analysis. Clin Infect Dis 77(6):883\u2013891 https:\/\/doi.org\/10.1093\/cid\/ciad290","journal-title":"Clin Infect Dis"},{"key":"4597_CR117","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-025-05108-6","author":"J Torre-Cisneros","year":"2025","unstructured":"Torre-Cisneros J et al (2025) Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study. Eur J Clin Microbiol Infect Dis. https:\/\/doi.org\/10.1007\/s10096-025-05108-6","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"4597_CR118","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.cmi.2023.05.008","volume":"29","author":"P Sendi","year":"2023","unstructured":"Sendi P et al (2023) Early switch from intravenous to oral antibiotic treatment in bone and joint infections. Clin Microbiol Infect 29(9):1133\u20131138 https:\/\/doi.org\/10.1016\/j.cmi.2023.05.008","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"4597_CR119","doi-asserted-by":"crossref","first-page":"14689","DOI":"10.1002\/jcp.28225","volume":"234","author":"JY Sharahi","year":"2019","unstructured":"Sharahi JY et al (2019) Advanced strategies for combating bacterial biofilms. J Cell Physiol 234(9):14689\u201314708\u00a0 https:\/\/doi.org\/10.1002\/jcp.28225","journal-title":"J Cell Physiol"},{"key":"4597_CR120","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01194-20","author":"ChristineA Pybus","year":"2021","unstructured":"Pybus Christine A et al (2021) Cefiderocol retains antibiofilm activity in multidrug-resistant gram-negative pathogens. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.01194-20","journal-title":"Antimicrob Agents Chemother"},{"key":"4597_CR121","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jgar.2024.01.021","volume":"37","author":"C Ferretti","year":"2024","unstructured":"Ferretti C et al (2024) Evaluation of antibiofilm activity of cefiderocol alone and in combination with imipenem against Pseudomonas aeruginosa. J Glob Antimicrob Resist 37:53\u201361 https:\/\/doi.org\/10.1016\/j.jgar.2024.01.021","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"4597_CR122","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-016-0294-z","volume":"8","author":"A Langdon","year":"2016","unstructured":"Langdon A, Crook N, Dantas G (2016) The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med 8(1):39 https:\/\/doi.org\/10.1186\/s13073-016-0294-z","journal-title":"Genome Med"},{"key":"4597_CR123","volume":"15","author":"JJ Taitz","year":"2024","unstructured":"Taitz JJ et al (2024) Antibiotic-mediated dysbiosis leads to activation of inflammatory pathways. Front Immunol 15:1493991\u00a0 https:\/\/doi.org\/10.3389\/fimmu.2024.1493991","journal-title":"Front Immunol"},{"issue":"8","key":"4597_CR124","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02171-20","volume":"65","author":"EK McCreary","year":"2021","unstructured":"McCreary EK, Heil EL, Tamma PD (2021) New perspectives on antimicrobial agents: cefiderocol. Antimicrob Agents Chemother 65(8):e0217120 https:\/\/doi.org\/10.1128\/AAC.02171-20","journal-title":"Antimicrob Agents Chemother"},{"key":"4597_CR125","volume":"13","author":"C Wang","year":"2022","unstructured":"Wang C et al (2022) Cefiderocol for the treatment of multidrug-resistant gram-negative bacteria: a systematic review of currently available evidence. Front Pharmacol 13:896971 https:\/\/doi.org\/10.3389\/fphar.2022.896971","journal-title":"Front Pharmacol"},{"key":"4597_CR126","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02163-17","author":"Y Saisho","year":"2018","unstructured":"Saisho Y et al (2018) Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for gram-negative bacteria, in healthy subjects. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.02163-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"4597_CR127","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00228-018-2458-9","volume":"74","author":"T Katsube","year":"2018","unstructured":"Katsube T et al (2018) Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters. Eur J Clin Pharmacol 74(7):931\u2013938\u00a0https:\/\/doi.org\/ 10.1007\/s00228-018-2458-9","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"4597_CR128","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1089\/mdr.2023.0090","volume":"29","author":"L Malisova","year":"2023","unstructured":"Malisova L et al (2023) In vitro activity of cefiderocol against carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa. Microb Drug Resist 29(10):485\u2013491\u00a0 https:\/\/doi.org\/10.1089\/mdr.2023.0090","journal-title":"Microb Drug Resist"},{"issue":"3","key":"4597_CR129","doi-asserted-by":"crossref","first-page":"e856","DOI":"10.1093\/cid\/ciab026","volume":"73","author":"IP Safe","year":"2021","unstructured":"Safe IP et al (2021) Severe hypoxemia with normal heart and respiratory rate in early-stage coronavirus disease 2019 patients: the \u201chappy hypoxemia phenomenon.\u201d Clin Infect Dis 73(3):e856\u2013e858 https:\/\/doi.org\/10.1093\/cid\/ciab026","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4597_CR130","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40121-023-00773-6","volume":"12","author":"KS Kaye","year":"2023","unstructured":"Kaye KS et al (2023) Cefiderocol, a siderophore cephalosporin, as a treatment option for infections caused by carbapenem-resistant enterobacterales. Infect Dis Ther 12(3):777\u2013806 https:\/\/doi.org\/10.1007\/s40121-023-00773-6","journal-title":"Infect Dis Ther"},{"issue":"5","key":"4597_CR131","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s10096-025-05061-4","volume":"44","author":"MM Montero","year":"2025","unstructured":"Montero MM et al (2025) Addressing carbapenemase-producing extensively drug-resistant Pseudomonas aeruginosa: the potential of cefiderocol and ceftazidime\/avibactam plus aztreonam therapy. Eur J Clin Microbiol Infect Dis 44(5):1077\u20131087 https:\/\/doi.org\/10.1007\/s10096-025-05061-4","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"4597_CR132","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10096-021-04341-z","volume":"41","author":"G Bianco","year":"2022","unstructured":"Bianco G et al (2022) In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects. Eur J Clin Microbiol Infect Dis 41(1):63\u201370\u00a0 https:\/\/doi.org\/10.1007\/s10096-021-04341-z","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4597_CR133","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10060652","author":"DF Bavaro","year":"2021","unstructured":"Bavaro DF et al (2021) Cefiderocol-based combination therapy for \u201cdifficult-to-treat\u201d gram-negative severe infections: real-life case series and future perspectives. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics10060652","journal-title":"Antibiotics"},{"issue":"4","key":"4597_CR134","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10096-021-04397-x","volume":"41","author":"L Poirel","year":"2022","unstructured":"Poirel L et al (2022) Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants. Eur J Clin Microbiol Infect Dis 41(4):677\u2013680 https:\/\/doi.org\/10.1007\/s10096-021-04397-x","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"4597_CR135","first-page":"e00569","volume":"67","author":"M Khan Shahbaz","year":"2023","unstructured":"Khan Shahbaz M et al (2023) Combination of inhibitors for two glycolytic enzymes portrays high synergistic efficacy against Cryptosporidium parvum. Antimicrob Agents Chemother 67(10):e00569-e623 https:\/\/doi.org\/10.1128\/aac.00569-23","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"4597_CR136","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/cid\/ciad759","volume":"78","author":"F Senchyna","year":"2024","unstructured":"Senchyna F et al (2024) Sequential treatment failure with aztreonam-ceftazidime-avibactam followed by cefiderocol due to preexisting and acquired mechanisms in a New Delhi Metallo-\u03b2-lactamase\u2013producing Escherichia coli causing fatal bloodstream infection. Clin Infect Dis 78(6):1425\u20131428 https:\/\/doi.org\/10.1093\/cid\/ciad759","journal-title":"Clin Infect Dis"},{"key":"4597_CR137","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14020210","author":"G Granata","year":"2025","unstructured":"Granata G et al (2025) Combating metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa: the fractional inhibitory concentration index as a tool to evaluate antibiotic synergy. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics14020210","journal-title":"Antibiotics"},{"key":"4597_CR138","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11121681","author":"G Bianco","year":"2022","unstructured":"Bianco G et al (2022) Synergistic effect of clinically available beta-lactamase inhibitors combined with cefiderocol against carbapenemase-producing gram-negative organisms. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics11121681","journal-title":"Antibiotics"},{"key":"4597_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12050858","author":"M Palombo","year":"2023","unstructured":"Palombo M et al (2023) Synergistic activity of cefiderocol in combination with piperacillin-tazobactam, fosfomycin, ampicillin-sulbactam, imipenem-relebactam and ceftazidime-avibactam against carbapenem-resistant gram-negative bacteria. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics12050858","journal-title":"Antibiotics"},{"key":"4597_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00074","author":"M Bassetti","year":"2019","unstructured":"Bassetti M et al (2019) Treatment of infections due to MDR gram-negative bacteria. Front Med. https:\/\/doi.org\/10.3389\/fmed.2019.00074","journal-title":"Front Med"},{"issue":"11","key":"4597_CR141","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/ppul.24945","volume":"55","author":"AB Gainey","year":"2020","unstructured":"Gainey AB et al (2020) Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Pediatr Pulmonol 55(11):2990\u20132994\u00a0 https:\/\/doi.org\/10.1002\/ppul.24945","journal-title":"Pediatr Pulmonol"},{"key":"4597_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12010049","author":"A Marino","year":"2022","unstructured":"Marino A et al (2022) Intravenous fosfomycin: a potential good partner for cefiderocol. Clinical experience and considerations. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics12010049","journal-title":"Antibiotics"},{"key":"4597_CR143","doi-asserted-by":"publisher","unstructured":"Mercadante S et al (2024) The use of cefiderocol as salvage therapy in an infant receiving ECMO and continuous renal replacement therapy. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics13010037","DOI":"10.3390\/antibiotics13010037"},{"key":"4597_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/jfb13040174","author":"T Lupia","year":"2022","unstructured":"Lupia T et al (2022) Meropenem\/Vaborbactam and cefiderocol as combination or monotherapy to treat multi-drug resistant gram-negative infections: a regional cross-sectional survey from piedmont infectious disease unit network (PIDUN). J Funct Biomater. https:\/\/doi.org\/10.3390\/jfb13040174","journal-title":"J Funct Biomater"},{"key":"4597_CR145","doi-asserted-by":"crossref","unstructured":"Wunderink RG et al (2019) LB4. Efficacy and safety of Cefiderocol vs. high-dose meropenem in patients with nosocomial pneumonia\u2014results of a phase 3, randomized, multicenter, double-blind, non-inferiority study. Open Forum Infect Dis. 6(Supplement_2):S994\u2013S994 https:\/\/doi.org\/10.1093\/ofid\/ofz415.2487","DOI":"10.1093\/ofid\/ofz415.2487"},{"key":"4597_CR146","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12040772","author":"AH Mondal","year":"2024","unstructured":"Mondal AH et al (2024) A review on colistin resistance: an antibiotic of last resort. Microorganisms. https:\/\/doi.org\/10.3390\/microorganisms12040772","journal-title":"Microorganisms"},{"issue":"5","key":"4597_CR147","doi-asserted-by":"crossref","first-page":"e02142","DOI":"10.1128\/aac.02142-21","volume":"66","author":"M Falcone","year":"2022","unstructured":"Falcone M et al (2022) Cefiderocol\u2014compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 66(5):e02142-e2221 https:\/\/doi.org\/10.1128\/aac.02142-21","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4597_CR148","volume":"24","author":"Y Zhan","year":"2024","unstructured":"Zhan Y et al (2024) Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis. BMC Infect Dis 24(1):967\u00a0https:\/\/doi.org\/10.1186\/s12879-024-09899-5","journal-title":"BMC Infect Dis"},{"key":"4597_CR149","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10060652","author":"DF Bavaro","year":"2021","unstructured":"Bavaro DF et al (2021) Cefiderocol-based combination therapy for \u201cdifficult-to-treat\u201d gram-negative severe infections: real-life case series and future perspectives. Antibiotics (Basel). https:\/\/doi.org\/10.3390\/antibiotics10060652","journal-title":"Antibiotics (Basel)"},{"issue":"7","key":"4597_CR150","volume":"16","author":"CM Niculae","year":"2024","unstructured":"Niculae CM et al (2024) Tigecycline-based regimens for complicated urinary tract infections caused by carbapenem-resistant Gram-negative bacteria: case series. Cureus 16(7):e65617 https:\/\/doi.org\/10.7759\/cureus.65617","journal-title":"Cureus"},{"issue":"4","key":"4597_CR151","doi-asserted-by":"crossref","DOI":"10.3390\/ph15040463","volume":"15","author":"L Principe","year":"2022","unstructured":"Principe L et al (2022) Microbiological, clinical, and PK\/PD features of the new anti-gram-negative antibiotics: \u03b2-lactam\/\u03b2-lactamase inhibitors in combination and cefiderocol\u2014an all-inclusive guide for clinicians. Pharmaceuticals 15(4):463\u00a0 https:\/\/doi.org\/10.3390\/ph15040463","journal-title":"Pharmaceuticals"},{"key":"4597_CR152","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S246174","author":"X Tan","year":"2021","unstructured":"Tan X et al (2021) Therapeutic options for metallo-\u03b2-lactamase-producing enterobacterales. Infect Drug Resist. https:\/\/doi.org\/10.2147\/IDR.S246174","journal-title":"Infect Drug Resist"},{"issue":"10","key":"4597_CR153","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40261-020-00955-x","volume":"40","author":"YR Lee","year":"2020","unstructured":"Lee YR, Yeo S (2020) Cefiderocol, a new siderophore cephalosporin for the treatment of complicated urinary tract infections caused by multidrug-resistant pathogens: preclinical and clinical pharmacokinetics, pharmacodynamics, efficacy and safety. Clin Drug Investig 40(10):901\u2013913 https:\/\/doi.org\/10.1007\/s40261-020-00955-x","journal-title":"Clin Drug Investig"},{"issue":"3","key":"4597_CR154","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00150-21","volume":"35","author":"A Philippon","year":"2022","unstructured":"Philippon A et al (2022) Class C \u03b2-lactamases: molecular characteristics. Clin Microbiol Rev 35(3):e0015021 https:\/\/doi.org\/10.1128\/cmr.00150-21","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"4597_CR155","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/phar.2802","volume":"43","author":"A El-Ghali","year":"2023","unstructured":"El-Ghali A et al (2023) Sulbactam-durlobactam: a novel \u03b2-lactam-\u03b2-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections. Pharmacotherapy 43(6):502\u2013513 https:\/\/doi.org\/10.1002\/phar.2802","journal-title":"Pharmacotherapy"},{"issue":"4","key":"4597_CR156","volume":"19","author":"BJ M\u00e9ndez-Sotelo","year":"2024","unstructured":"M\u00e9ndez-Sotelo BJ et al (2024) In vitro activity of ceftazidime\/avibactam, cefiderocol, meropenem\/vaborbactam and imipenem\/relebactam against clinical strains of the Stenotrophomonas maltophilia complex. PLoS One 19(4):e0298577 https:\/\/doi.org\/10.1371\/journal.pone.0298577","journal-title":"PLoS One"},{"key":"4597_CR157","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-025-02527-7","author":"S Karakonstantis","year":"2025","unstructured":"Karakonstantis S, Ioannou P, Kofteridis DP (2025) Are cefiderocol or sulbactam\/durlobactam better than alternative best available treatment for infection by carbapenem-resistant A. baumannii? A systematic literature review. Infection. https:\/\/doi.org\/10.1007\/s15010-025-02527-7","journal-title":"Infection"},{"issue":"2","key":"4597_CR158","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens14020168","volume":"14","author":"A Katsarou","year":"2025","unstructured":"Katsarou A et al (2025) \u03b2-lactam\/\u03b2-lactamase inhibitor combination antibiotics under development. Pathogens 14(2):168 https:\/\/doi.org\/10.3390\/pathogens14020168","journal-title":"Pathogens"},{"key":"4597_CR159","unstructured":"Sakoulas G (2024) Innovative pairing of beta-lactamase inhibitors to combat multidrug-resistant gram-negative pathogens. NEJM J Watch NA57235"},{"key":"4597_CR160","doi-asserted-by":"crossref","unstructured":"Tamma PD et al (2024) Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis ciae403 https:\/\/doi.org\/10.1093\/cid\/ciae403","DOI":"10.1093\/cid\/ciae403"},{"issue":"4","key":"4597_CR161","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","volume":"18","author":"M Paul","year":"2018","unstructured":"Paul M et al (2018) Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 18(4):391\u2013400 https:\/\/doi.org\/10.1016\/S1473-3099(18)30099-9","journal-title":"Lancet Infect Dis"},{"key":"4597_CR162","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40121-021-00412-y","volume":"10","author":"D Yahav","year":"2021","unstructured":"Yahav D, Shepshelovich D, Tau N (2021) Cost analysis of new antibiotics to treat multidrug-resistant bacterial infections: mind the gap. Infect Dis Ther 10:621\u2013630 https:\/\/doi.org\/10.1007\/s40121-021-00412-y","journal-title":"Infect Dis Ther"},{"issue":"1","key":"4597_CR163","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1016\/j.jval.2021.11.521","volume":"25","author":"M Bassetti","year":"2022","unstructured":"Bassetti M et al (2022) POSC116 economic evaluation of cefiderocol in patients with confirmed carbapenem-resistant infections in the Italian healthcare system. Value Health 25(1):S110 https:\/\/doi.org\/10.1016\/j.jval.2021.11.521","journal-title":"Value Health"},{"issue":"1","key":"4597_CR164","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.jval.2021.11.520","volume":"25","author":"M Bassetti","year":"2022","unstructured":"Bassetti M et al (2022) POSC115 cost effectiveness economic evaluation of cefiderocol for the treatment of suspected carbapenem-resistant infections in Italy. Value Health 25(1):S109 https:\/\/doi.org\/10.21203\/rs.3.rs-2620731\/v1","journal-title":"Value Health"},{"issue":"12","key":"4597_CR165","doi-asserted-by":"publisher","first-page":"S206","DOI":"10.1016\/j.jval.2024.10.1051","volume":"27","author":"K Bukhari","year":"2024","unstructured":"Bukhari K et al (2024) EE771 cost-effectiveness analysis of cefiderocol versus imipenem\/cilastatin for treatment of complicated urinary tract infection in hospitalized patients using ChatGPT and TreeAge. Value Health 27(12):S206\u00a0 https:\/\/doi.org\/10.1016\/j.jval.2024.10.1051","journal-title":"Value Health"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-025-04597-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-025-04597-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-025-04597-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T13:15:30Z","timestamp":1770383730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-025-04597-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":165,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4597"],"URL":"https:\/\/doi.org\/10.1007\/s00284-025-04597-0","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"25"}}